SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov
SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.
How this was made
The 30-second read
Why it matters
The company claims statistically significant and clinically meaningful overall survival improvement at the pre-specified 80-death analysis, with no new safety signals, and outlines next steps toward FDA discussion and BLA preparations for 1H 2027.
Market read
This is a pivotal clinical readout with primary endpoint OS significance and an explicit regulatory timeline, creating a near-term decision point for biotech risk pricing.
What to watch
Accelerated filing strategy depends on FDA feedback; trial design details (open-label, BAT composition) and the strength of confirmatory evidence could influence ultimate approval odds.
Background
REGAL is a pivotal randomized Phase 3 trial of galinpepimut-S (GPS) as AML maintenance monotherapy in patients in second or later complete remission who are ineligible for or unable to undergo allogeneic stem cell transplantation.
Ticker impact
SELLAS reports REGAL Phase 3 topline success for galinpepimut-S, with OS hazard ratio 0.59 (p=0.035) and plans FDA meeting plus BLA prep.
Likely upward bias as traders price in improved regulatory odds and a clearer path to an accelerated BLA timeline.
The article discloses primary endpoint achievement with statistically significant OS benefit, plus stated intent to engage FDA and prepare a BLA submission in 1H 2027.
Market effects
Reinforces investor appetite for WT1-targeted immunotherapy and late-stage AML maintenance vaccine strategies.
Primarily US biotech sentiment, with potential spillover to AML-focused peers on perceived competitive validation.
Limited direct global macro impact; mainly affects global AML immunotherapy development expectations.
Counterpoint
Topline OS benefit may not fully de-risk the program until secondary endpoints, subgroup consistency, and detailed safety are reviewed at a medical conference and in the full dataset.
Key entities
- companySELLAS Life Sciences Group, Inc.
NASDAQ-listed late-stage clinical biopharmaceutical company announcing positive pivotal Phase 3 REGAL results for GPS.
- productGalinpepimut-S (GPS)
WT1-targeted off-the-shelf immunotherapeutic cancer vaccine evaluated as AML maintenance therapy.
- clinical_trialREGAL trial
Phase 3 randomized registrational trial evaluating GPS in AML patients in second or later remission who cannot undergo transplant.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory authority SELLAS plans to meet to discuss an accelerated filing strategy and regulatory path forward.

